Innoviva Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Innoviva şirketinin kazançları yıllık ortalama -12.5% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 12.9% oranında artan oldu. Gelirler yıllık ortalama 1.8% oranında artan oldu. Innoviva şirketinin öz sermaye getirisi 9.7% olup, net marjı 18.3% dir.

Anahtar bilgiler

-12.5%

Kazanç büyüme oranı

-1.5%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	7.3%
Gelir büyüme oranı	1.8%
Özkaynak getirisi	9.7%
Net Marj	18.3%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Innoviva nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:HVE Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	353	65	111	-21
30 Jun 24	330	145	113	0
31 Mar 24	312	181	109	0
31 Dec 23	310	180	98	0
30 Sep 23	290	50	84	31
30 Jun 23	290	233	83	0
31 Mar 23	318	233	71	0
31 Dec 22	331	214	58	0
30 Sep 22	373	293	46	0
30 Jun 22	404	99	21	0
31 Mar 22	396	188	13	0
31 Dec 21	392	266	16	0
30 Sep 21	375	309	17	0
30 Jun 21	365	265	17	0
31 Mar 21	344	253	16	0
31 Dec 20	337	224	12	0
30 Sep 20	322	216	8	0
30 Jun 20	299	228	9	0
31 Mar 20	285	189	11	0
31 Dec 19	261	157	15	0
30 Sep 19	265	375	17	0
30 Jun 19	261	382	13	0
31 Mar 19	264	399	13	0
31 Dec 18	261	395	19	0
30 Sep 18	251	190	17	0
30 Jun 18	238	166	24	0
31 Mar 18	229	147	30	0
31 Dec 17	217	134	32	0
30 Sep 17	191	101	35	0
30 Jun 17	176	92	32	0
31 Mar 17	150	72	28	0
31 Dec 16	134	60	23	0
30 Sep 16	113	38	22	0
30 Jun 16	93	19	22	0
31 Mar 16	71	-4	21	0
31 Dec 15	54	-19	20	0
30 Sep 15	38	-39	21	0
30 Jun 15	26	-56	25	0
31 Mar 15	16	-68	29	0
31 Dec 14	8	-74	35	0
30 Sep 14	3	-66	35	0
30 Jun 14	2	-55	32	0
31 Mar 14	2	-9	27	0
31 Dec 13	5	-31	24	0

Kaliteli Kazançlar: HVE büyük bir tek seferlik zarar ile $98.4M, 30th September, 2024 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: HVE 'nin mevcut net kar marjları (18.3%) geçen yılın (17.2%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: HVE şirketinin kazançları son 5 yılda yılda 12.5% oranında azaldı.

Büyüme Hızlandırma: HVE 'un son bir yıldaki kazanç büyümesi ( 29.5% ) 5 yıllık ortalamasını (yıllık -12.5% ) aşıyor.

Kazançlar vs. Sektör: HVE geçen yılki kazanç büyümesi ( 29.5% ) Pharmaceuticals sektörünün 28.7% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: HVE 'nin Özsermaye Getirisi ( 9.7% ) düşük olarak değerlendiriliyor.

Innoviva Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings released: EPS: US$0.019 (vs US$1.26 in 3Q 2023)

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.02 profit in 2Q 2023)

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.51 in 1Q 2023)

Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022)

Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022)

Second quarter 2023 earnings released: EPS: US$0.02 (vs US$0.013 in 2Q 2022)

Recent updates

Third quarter 2024 earnings released: EPS: US$0.019 (vs US$1.26 in 3Q 2023)

New minor risk - Financial position

New minor risk - Profit margin trend

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.02 profit in 2Q 2023)

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

New minor risk - Financial position

Now 21% undervalued after recent price drop

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.51 in 1Q 2023)

Innoviva, Inc., Annual General Meeting, Jun 17, 2024

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.’s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022)

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Chief Accounting Officer & Secretary recently sold €142k worth of stock

Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022)

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Audit Committee Composition Requirements

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.02 (vs US$0.013 in 2Q 2022)

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

First quarter 2023 earnings released: EPS: US$0.51 (vs US$0.23 in 1Q 2022)

Full year 2022 earnings released: EPS: US$3.07 (vs US$3.24 in FY 2021)

Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors

Innoviva, Inc Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam

Third quarter 2022 earnings released: EPS: US$3.81 (vs US$1.04 in 3Q 2021)

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $100 million worth of its shares.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of La Jolla Pharmaceutical Company (NasdaqCM:LJPC).

Second quarter 2022 earnings released: EPS: US$0.013 (vs US$1.01 in 2Q 2021)

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 15% stake in Theravance Respiratory Company, LLC from Innoviva, Inc. (NasdaqGS:INVA).

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

First quarter 2022 earnings released: EPS: US$0.23 (vs US$0.93 in 1Q 2021)

Investor sentiment improved over the past week

Innoviva, Inc. (NasdaqGS:INVA) submitted a non-binding proposal to acquire all of the remaining shares of Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX).

Independent Chairman of the Board recently bought €216k worth of stock

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for 32,000,000 shares, representing 32% for $392 million.

First quarter 2021 earnings released: EPS US$0.93 (vs US$0.65 in 1Q 2020)

Innoviva, Inc. Appoints Deborah L. Birx to its Board of Directors

Full year 2020 earnings released: EPS US$2.22 (vs US$1.56 in FY 2019)

Revenue beats expectations

Full year 2020 earnings released: EPS US$2.21 (vs US$1.56 in FY 2019)

Revenue beats expectations

New 90-day high: €10.20

New 90-day high: €10.00

Investor sentiment improved over the past week

Innoviva, Inc. Enters into Strategic Partnership with Sarissa Capital Management LP

Third quarter earnings released

New 90-day low: €8.40

New 90-day low: €9.25

New 90-day low - €10.60

New 90-day low - €11.10

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin